Nasdaq · CIK 0000875320 · PHARMACEUTICAL PREPARATIONS
VERTEX PHARMACEUTICALS INC / MA
VRTX chart by TradingView
PRICE HISTORY
LIVE · NASDAQVRTX chart by TradingView
- REVENUE FY2025 ENDED DEC 2025
- $12.0B
- EBITDA
- $4.4B
- FREE CASH FLOW
- $3.2B
- EPS
- $15.32
- GROSS MARGIN
- 86.24%
- ROIC
- —
Q2 FY26ENDED JUN 2026HOVERDRAG ACROSS ANY CHART TO SCRUB ALL 24 · 40 QUARTERS SHOWNVALUATIONGROWTHPROFITABILITY & RETURNSCASH & CAPITALBALANCE SHEET
VALUATION
what you pay for a unit of the business7 CHARTS⤢
P / E RATIO (TTM)
28.8x
-81%20.4x194.4x
⤢
P / SALES (TTM)
10.1x
-22%6.6x17.7x
⤢
P / BOOK
6.3x
-70%4.9x21.2x
⤢
EV / EBITDA (TTM)
—
⤢
EV / REVENUE (TTM)
—
⤢
FCF YIELD (TTM)
2.99%
+2.7pp-0.99%5.42%
⤢
DIVIDEND YIELD (TTM)
—
GROWTH
is the business getting bigger5 CHARTS⤢
REVENUE
$3.3B
+706%⤢
EBITDA (DERIVED)
$1.3B
+$1.3B⤢
NET INCOME
$1.1B
+$1.1B⤢
EPS (DILUTED)
$4.31
+$4.47⤢
REVENUE GROWTH YOY
12.45%
-21.1pp-10.34%79.54%
PROFITABILITY & RETURNS
what survives to the bottom, and what it earns on capital4 CHARTS⤢
FCF MARGIN
30.39%
+17.9pp-144.49%66.95%
⤢
RETURN ON CAPITAL
—
⤢
RETURN ON EQUITY (TTM)
21.76%
+43.2pp-21.41%47.28%
MARGIN FUNNEL
every line is a share of the same revenue, so they read on one scale — the gaps are what each layer takes out, and net rises above operating when income arrives from outside the businessGROSS MARGIN85.33%
OPERATING MARGIN37.40%
NET MARGIN32.99%
FCF MARGIN30.39%
CASH & CAPITAL
where the money actually goes5 CHARTS⤢
FREE CASH FLOW
$1.0B
+1857%⤢
STOCK-BASED COMP
$0.2B
+178%⤢
CAPITAL EXPENDITURE
$0.1B
+708%⤢
SHARES OUTSTANDING
0.26B
+4%⤢
DIVIDEND / SHARE
—
BALANCE SHEET
how much cushion there is3 CHARTS⤢
CASH & EQUIVALENTS
$6.1B
+754%⤢
TOTAL DEBT
—
⤢
DEBT / EBITDA (TTM)
—
OWNERSHIP
10 LARGEST HOLDERS · WHO OWNS THE FLOATINSTITUTIONS 98.75%INSIDERS 0.21%OTHER / RETAIL 1.04%2,411 INSTITUTIONAL FILERS
| HOLDER | % HELD | SHARES | VALUE | CHANGE |
|---|---|---|---|---|
| Capital World Investors | 10.00% | 25.4M | $12.58B | -0.6% |
| Blackrock Inc. | 9.44% | 24.0M | $11.89B | +0.9% |
| Capital Research Global Investors | 8.32% | 21.1M | $10.48B | +22.0% |
| Vanguard Capital Management LLC | 6.51% | 16.5M | $8.19B | NEW |
| State Street Corporation | 4.62% | 11.7M | $5.82B | +0.3% |
| Invesco Ltd. | 3.11% | 7.9M | $3.92B | +0.5% |
| JPMORGAN CHASE & CO | 2.77% | 7.0M | $3.49B | +16.5% |
| Geode Capital Management, LLC | 2.42% | 6.1M | $3.05B | +2.6% |
| Vanguard Portfolio Management LLC | 2.03% | 5.1M | $2.55B | NEW |
| Capital International Investors | 2.02% | 5.1M | $2.54B | +8.3% |
AS OF 2026-03-31 · MOST RECENT 13F FILINGS
SOURCE → 10-K · 10-Q · 8-K / GUIDANCE · ALL FILINGS
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.